COMP <GO>
ATRC vs ABBV // ALTMAN Z-SCORE & DEBT/EQUITY
AtriCure Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ATRC 5
— ABBV 6
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: ATRC
LAST: $61.25 (-1.97%) • MKT CAP: $3.18B
balance-sheet
12.08
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
balance-sheet
5.33
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ATRC VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ATRC | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 75.00% | 70.20% | +4.80 | ATRC | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -1.90% | 29.00% | -30.90 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.52% | 3.47% | -1.95 | ABBV | /fcf-yield <GO> |
| Operating Margin | -1.80% | 24.60% | -26.40 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -2.10% | 6.90% | -9.00 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 14.90% | 8.60% | +6.30 | ATRC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 12.08 | 5.33 | +6.75 | ATRC | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | ATRC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.0 | 65.1 | +0.90 | ATRC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.18B | $513.86B | -$510.68B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ATRC REV | ABBV REV | ATRC GROSS % | ABBV GROSS % | ATRC FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $534.5M | $61.16B | 75.0% | 70.2% | $48.3M | $17.82B |
| FY 2024 | $465.3M | $56.33B | 74.7% | 70.0% | $745.0K | $17.83B |
| FY 2023 | $399.2M | $54.32B | — | — | $4.5M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ATRC // BETA —
ABBV // BETA 1.15